A Practical Guide to Understanding and Treating Peripheral Artery Disease.
Maya R ChilbertAshley E WoodruffKelly C RogersPublished in: Journal of cardiovascular pharmacology (2024)
Peripheral arterial disease (PAD) is the third leading cause of atherosclerotic morbidity after coronary heart disease and stroke yet is widely underdiagnosed and undertreated. Treatment of risk factors such as diabetes and cigarette smoking can benefit patients with PAD. Patients should have adequate blood pressure and lipid control to decrease clinical manifestations and symptoms of PAD. Use of antithrombotic medications should be individualized to the patient depending on the presence of symptoms, revascularization, and comorbidities. All patient care providers, including physicians, pharmacists, nurse practitioners, and physician assistants, should incorporate PAD screening in their at-risk patients to improve access for appropriate earlier diagnosis, initiation of guideline directed therapy, and risk factor modification to reduce both major adverse CV and limb outcomes. The purpose of this narrative review is to provide an overview of PAD and summarize clinical trial evidence and guideline recommendations for screening and treatment to increase awareness among health care providers to ultimately have a positive impact on patient care.
Keyphrases
- risk factors
- end stage renal disease
- primary care
- blood pressure
- healthcare
- clinical trial
- newly diagnosed
- chronic kidney disease
- ejection fraction
- type diabetes
- cardiovascular disease
- emergency department
- prognostic factors
- peripheral artery disease
- peritoneal dialysis
- coronary artery disease
- randomized controlled trial
- coronary artery bypass grafting
- skeletal muscle
- cell therapy
- adipose tissue
- weight loss
- metabolic syndrome
- open label
- social media
- health information
- acute coronary syndrome
- study protocol
- health insurance
- phase iii
- subarachnoid hemorrhage
- adverse drug